Relmada Therapeutics (RLMD) Misses Q1 EPS by 1c

Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.22), $0.01 worse than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• List of suppliers, parts, photos of iPhone 18 Pro are part of Tata Electronics data breach - Reuters
• Biohaven Pharma (BHVN) call put ratio 7.5 calls to 1 put as share price down 4.7%
• Iran's foreign ministry spokesperson: no talks with the U.S. in coming days